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TARGETS OF HSA-MIR-488* IN HUMAN PROSTATE CARCINOMA CELLS 
JINANI ELIAS SLAIBI 
ABSTRACT 
 
Prostate cancer (PCa) is one of the most prevalent forms of cancer among 
men in America and is second only to lung cancer as a cause of cancer-related 
deaths in men. Recent epidemiological study shows that one in every six men 
over the age of forty five is at risk of PCa. Androgen receptor (AR) plays a 
causative role in the development of PCa. Hormonal blockade therapy which 
inhibits the expression of AR eventually fails and disease progresses to fatal 
androgen-refractory stage from androgen-dependent stage. Therefore, novel 
molecular approaches which can target and block the expression of AR are 
required. We propose that microRNAs (miRNA) that function as negative gene 
regulators have potential as PCa therapeutics. Using bioinformatics methods, we 
have identified that human miRNA hsa-miR-488* has potential to modulate AR 
expression. In the present study, we have validated the target site in AR 3’UTR 
and established that AR is a target of Hsa-miR-488*. Our data show that the 
ectopically expressed hsa-miR-488* as well as the synthetic miRNA mimic can 
suppress the expression of luciferase activity in chimeric plasmid harboring 
AR3’UTR with dose dependent effects. In addition, miR-488* negatively 
regulated the expression of endogenous androgen receptor in PCa cells LNCaP. 
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Thus hsa-miR-488* that function as negative gene regulators has potential as 
PCa therapeutics. 
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CHAPTER I 
INTRODUCTION 
 
1.1 Cancer: 
 
Human body is made up of about 100 trillion of living cells (Campbell, N.A. et 
al. 2006). Normal cells carry a complete organismic genome which is far more 
information that any cell may require (Sinden, R.R. 1994).  Regulation of the cell 
cycle is critical for the development of multicellular organisms. Part of this 
information in normal cells controls essential function for the normal survivor of 
cells such as growth, dividing, and dying in an orderly way. However, cancer 
cells have lost the ability to control growth and division leading to uncontrolled 
proliferation and the inappropriate survival of damaged cells. This new fate of the 
uncontrolled cells is responsible for the formation of tumors.    
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Cells have developed several safeguards to ensure that cell division, 
differentiation and death occur correctly and in a coordinated fashion, both during 
development and in the adult body (Esquela-Kerscher A. et al., 2006). Mutations 
into this genomic information divert cells into acquiring novel of abnormal 
phenotypes and incompatible features with normal cell cycle. These mutations 
may cause inability of cells to make a functional signal, or cause it to code for a 
protein that sends an incorrect signal to the cell (Kinzler K.W. et al. 2002). Most 
mutations are repaired by the cell, but in rare cases mutations do not get 
repaired. If a mutation is not repaired before a cell copies its DNA and divides 
into two cells, then the mutation is passed on to the two new daughter cells and 
becomes permanent. Some genetic disorders may cause cells deprivation of 
their ability to repair DNA, and may therefore experience buildup of mutations. 
Not all the mutations within the cell's DNA have effect on whether the cell will 
become cancerous or not (Sawyer S.A. et al. 2007). However, protein signals 
coded by a very small proportion of the total genes in each cell regulate cell 
growth and division. These regulatory genes include the two groups of genes 
called Proto-oncogenes and tumor-suppressor (Chial, H.  2008). A series of 
mutations in the DNA of either and/or both groups of these growth controlling 
genes is selected in cancerous cells. Thus cancer is considered to be a genetic 
disease and the cancer-forming process is called Tumorigenesis or 
Oncogenesis, where most cancers may arise through a combination of avoidable 
or unavoidable carcinogens (Lutz W.K. et al, 1988). 
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Many factors contribute to the transformation of normal cells into malignant 
cancerous cells such as exposure to carcinogens, genetic defects, life style or 
even viruses (Couch D.B. 1996). Cancer cells have gained the ability to grow and 
multiply out of control forming a large mass of tissue called a tumor. Some 
tumors are limited to one location and can be surgically removed. These tumors 
do not grow in an unlimited, aggressive manner, do not invade surrounding 
tissues and do not metastasize. This type of tumors is termed benign tumor 
(Ramzi C.et al. 1999). But in other cases of cancer, cells have gained the ability 
to spread and metastasize to surrounding tissue or other organs of the body. 
Such aggressive tumors are termed malignant. The term cancer is used to 
describe malignant, non benign tumors.  
 
1.2 Prostate cancer remains a significant public health problem in the U.S. 
 
Prostate cancer is the most common solid tumor form of cancer among men 
in America and is second only to lung cancer as a cause of cancer-related 
mortality (Jemal A. et al. 2008, 2005 ; Parker S.L et al. 1997). Despite earlier 
diagnosis and improvement in treatment modalities, the cancer’s projection for 
2009 estimated that 192,280 new cases of prostate cancer will occur in the US 
during 2009 and 27,360 men will die from the disease (ACS, 2009). 
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Figure 1: Statistical figures were adopted from the 2009 American cancer Society 
statistical study and rearranged in order to show the comparison between occurrence of 
cancer cases and the mortality rate of each site.  Prostate cancer is the most diagnosed 
cancer within men and the second cause of cancer death in American men.  
Numerous studies have shown that approximately 85% of newly diagnosed 
prostate cancer cases are localized in the prostate, and the remaining 15 % of 
the cases represents invasive or metastatic disease (Cooperberg MR et al. 
2004). Those studies have provided insight into molecular mechanisms that 
contribute to the beginning and progression of prostate cancer. Most of these 
studies have suggested that androgens play an important role in the 
development, regulation and progression of prostate cancer. Hence, the first line 
for treatment is the Androgen deprivation therapy either surgical or chemical 
castration through a complete hormonal blockage of androgen by using anti-
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androgens and in most cases combined with radiation in specific settings 
(Harries W. et al, 2009; Taneja S.S, 2003).  While most patients with prostate 
cancer initially respond to androgen-ablation therapy, however 20% are 
refractory to such treatments. Furthermore, majority of the patients who respond 
to androgen ablation therapy eventually relapse with androgen-independent 
prostate cancer (AIPC) within three years (Calabro F. et al, 2007). 
 
1.3 Two stages of Prostate cancer: 
 
The ligand-activated transcription factor, androgen receptor (AR), plays a 
central role in the development and progression of prostate cancer in humans. 
AR is heterogeneously expressed in primary tumors and throughout the 
progression of androgen dependent and androgen independent ‘hormone-
refractory prostate cancers.  Prostate cancer initiates as an androgen-dependent 
disease, and further accumulation of multiple sequential genetic and epigenetic 
alterations transforms it into an aggressive, therapy resistant, androgen-
independent prostate cancer (AIPC) (Maitland J.N. et al, 2008).  
The molecular basis of the transition from androgen dependent to AIPC is still 
unclear however; recent studies suggest that hypersensitivity of AR to trace level 
androgens combined with androgen ablation therapy could provide a selective 
pressure on the cellular pathways which are regulated by androgen signaling 
(Taplin, N.E et al, 1999; Craft N. et al, 1999). Consequently, androgen dependent 
cancer cells adapt to the androgen-deprived conditions and furthermore select 
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mutated AR that is able to utilize an anti-androgen antagonist as an agonist for 
their aggressive growth and proliferation (Marques, R.B et al, 2005). 
Despite all the evidences, it is far from clear as to how AIPC arises and the 
definitive roles played by the AR.  
 
1.4 Mechanism of action of Androgen receptor: 
 
Prostate cancer is dependent on androgen stimulation mediated by the 
androgen receptor (AR). AR, a steroid hormone receptor member of the large 
nuclear receptor superfamily, is a ligand activated transcription factor that 
regulates the growth and the development of the normal prostate and plays a key 
role in the pathogenesis of prostate cancer (Balk S.P et al., 2002; Quigley C.A et 
al.1995).  
Androgens stimulate proliferation and inhibit apoptosis, thus maintain the 
ratio of proliferating cells to those dying. The maintenance of this ratio is very 
critical for the normal growth of prostate cells (Feldman B.J and Feldman D., 
2001). Testosterone and diyhdrotestosterone (DHT) are the major androgens in 
men. Testes produce over 90% of the hormone testosterone and the remaining 
small fraction 5-10 % is synthesized in the adrenal glands. The largest 
concentration of testosterone is circulating in the body, while most of the DHT’s 
concentration is present in the prostatic tissues (Labrie FMD, 2004). About 75 % 
of DHT is produced by the prostate and the skin while the remaining 25 % 
circulating DHT is produced by the testes (Imamoto T. et al. 2008). 
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Figure 2: Mechanism of action of Androgen receptor: Testosterone enters cell 
membrane to the cytoplasm, were it is converted to DHT by 5 alpha-reductase enzyme 
(5αR). In the presence of DHT, AR will dissociate from the HSP and bind to DHT, 
leading to conformational changes in the AR. Upon the phosphorylation of AR 
homodimer it enters the nucleus and binds to the genes containing the androgen 
response element, resulting in biological responses. Bartel et al 2004. 
After being secreted by the testes, the testosterone hormone circulates in the 
blood flow. When it reaches the prostatic tissues, the testosterone enters the 
prostate cell membrane to the cytoplasm. In the cytoplasm, almost 90% of the 
testosterone is converted by 5 alpha-reductase enzyme (5αR) to DHT. 
Diyhdrotestosterone has much stimulatory effect on prostate cells growth 
 8 
 
compared to testosterone and it has 5 fold higher affinities for AR than 
testosterone (Feldman and Feldman, 2001; Montgomery et al 2009).  
Androgen receptor contains an N-terminal domain which is known as the 
regulatory domain and contains also two other domains: the first is a DNA 
binding domain (DBD) and the second is the ligand binding domain (LBD). In 
addition, AR has a hinge region that connects the Ligand binding domain to the 
DNA binding domain, followed by C-terminal domain (Brinkmann A.O., et al 
1989). 
In basal state, AR binds to the heat shock protein complex (HSP). This 
binding has the role of a chaperone to maintain the AR in a ligand-binding 
conformation (Balk S.P, 2002). In the presence of DHT, AR dissociates from the 
HSP and bind to DHT. This interaction leads to conformational changes in the 
AR and results in the formation of a homodimer which is phosphorylated by 
protein Kinase A (Feldman & Feldman, 2001; Balk S.P, 2002; Lynne V. et al, 
1996). 
 Upon the dimerization and phosphorylation of androgen receptor, the 
newly formed complex enters the nucleus where it binds to the androgen 
response element in the promoter regions of the target gene (Chen C.Z et al, 
2004). This binding will lead to the recruitment of co-activators and co-repressors 
which results in biological responses by triggering the translation process leading 
to up or down regulation of specific gene transcription (Feldman & Feldman, 
2001; Balk S.P, 2002). 
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 Up-regulation or activation of transcription results in increased synthesis of 
mRNA which in turn is transcribed by ribosomes to produce specific proteins. 
Thus a change in the levels of specific proteins in cells is one way by which 
androgen receptors control cell behavior.  
 
1.5 Regulatory noncoding microRNAs (miRNAs): 
 
MicroRNAs are a large family of phylogenetically conserved short, 
endogenous, single-stranded, 20-25 nucleotide long, noncoding RNAs molecules 
that can regulate gene expression in many different organisms ranging from 
viruses to plant to worm and humans (Lee R.C et al, 1993; Chen C.Z et al., 2004; 
Pasquinelli A.E. et al, 2000) ( Appendix: Table I and Figure I) . The best known 
founding members of this family are lin-4 and let-7 of Caenorhabditis elegans 
(Lee R.C et al, 1993; Pasquinelli A.E. et al, 2000). To date, more than 10,884 
miRNAs have been annotated and 721 of these are human miRNAs. (miRbase, 
Release 14, Sep 2009). These numbers are likely to change when many more 
tissue specific miRNAs would be discovered by small RNA cloning and 
sequencing strategies. miRNAs regulate the expression of thousands of target 
mRNAs; each target mRNA has been predicted to be regulated by multiple 
miRNAs.  
Computational analysis suggests that over 30% of human genes are 
regulated by miRNAs. Genes that are potentially targeted by these miRNAs 
include cell growth and maintenance, signal transduction, cell proliferation, 
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phosphorylation, cell cycle, transcription factors, cell organization and biogenesis 
(Nilsen T., 2007). In animals, miRNA mediates gene expression through 
translational repression of its target mRNA by binding at the 3’ untranslated 
region (UTR) in imperfect complementarity (Wightman B. et al, 1991).   
Many examples of documented miRNA functions were discovered in 
animals and include regulation of signaling pathways, apoptosis, metabolism, 
cardiogenesis and brain development (He L. and Hannon J., 2004).  
miRNAs may play a critical role in the process of tumorigenesis since a 
deregulation of these biological processes are frequently occurred in human 
cancer (Wenyong Z., et al., 2007). Evidence suggests that miRNAs can 
contribute to carcinogenesis by acting as tumor suppressors or oncogenes since 
they usually suppress the expression of oncogenes or proliferation related genes 
(Xu-Bao S., et al., 2008).  For instance, miR-15a and miR-16-1 are deleted or 
down-regulated in the majority of Chronic Lymphocytic Leukemia (CLL) and 
negatively regulate the antiapoptotic B cell lymphoma 2 (Bcl2) protein resulting in 
induced apoptosis in a leukemic cell line model. (Cimmino A., et al. 2005). 
Although many miRNAs are found to be significantly differentially expressed in 
different cancer types, to date, only a few have been well characterized for their 
functional significance.   
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1.6 Relative genomic location of miRNA: 
 
Scientists identified three groups of miRNA genes based on genomic location 
relative to protein coding gene locus: 
1. Intronic miRNA in protein coding transcription units (61%) e.g: miR-10 in 
HOX4B gene (Lagos-Quintana et al., 2003; Lim L.P et al., 2003). 
2. Intronic miRNA in noncoding transcription units (18%) e.g: miR-15a-16-1 
cluster found in the fourth intron of a previously defined noncoding RNA 
gene, DLEU2. (Narry K. and Jin-Wu N., 2006) 
3. Exonic miRNA in noncoding transcription units (20%), such as miR-155. 
(Cai X. et al, 2004; Lee et al., 2004). 
MicroRNA genes are found in regions of the genome as separate transcriptional 
units as well as in clusters of polycistronic units coding for several miRNAs. It 
was found that approximately half of known miRNA exist in non-protein coding 
RNAs (intron and exon) or within the intron of protein coding genes (Erdmann, 
V.A., et al. 2004). 
MicroRNAs that reside in introns share the same promoters and regulatory 
elements of their host gene (Sikand K. et al., 2009) as for the other miRNA genes 
transcribed from their own promoters, few primary transcripts have been entirely 
identified (Lagos-Quintana M., et al., 2001; Lau N.C. et al.,  2001). 
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Computational analysis suggested that 60% of protein encoding genes may be 
regulated by miRNAs. This fact suggests some important, yet undiscovered 
regulatory mechanisms linked to miRNAs. A significant number of miR genes 
(52.5%) are in cancer-associated genomic regions or fragile sites (FGA) (Calin 
G.A. et al., 2004). 
1.7 microRNAs Processing: 
 
Little is known about transcriptional processes for miRNAs. It has been 
shown that miRNAs control gene expression by binding to the complementary 
sites in the 3’ untranslated regions (3’UTRs) of target mRNAs and triggering 
therefore either translational inhibition or mRNA degradation by a molecular 
mechanism that is actively investigated (Wightman B. et al, 1991; Zamore D., 
2005; Hutvagner & Zamore, 2002). 
The majority of microRNAs are transcribed by RNA polymerase II from 
different genomic locations as long primary transcript of about 125 nucleotides in 
length, with a stem-loop structure known as (pri-miRNA) (Figure 3) (Lee et al, 
2002; Cai X. et a.l, 2004; Kim V.N et al., 2005). Initially it was thought that 
miRNAs are transcribed by RNA polymerase III (PolIII) (Cai X. et al, 2003), 
however some of the pri-miRNAs are several kilobases long hosting some 
stretches of more than 4 uracile nucleotides, which is unfavored by Pol III and will 
ultimately lead to the termination of transcription by Pol III (Lee Y. et al., 2004). 
Recently it is believed that Pol II is responsible for transcribing the majority of 
miRNAs (Cai X. et al, 2004; Kim V.N et al., 2005).  
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Subsequent to transcription in the nucleus, the pri-miRNAs are further 
processed by Drosha, RNase-III endonuclease. This enzyme belongs to the 
family of double stranded RNA specific ribonucleases (Cai X. et al, 2003). 
Drosha functions as a large protein complex called Microprocessor complex. This 
large nuclear protein complex (about 550 kDa) plays the role of pri-miRNAs 
metabolizing machinery.  The Microprocessor is composed of the enzyme 
Drosha bound to a dsRNA-binding protein known as DGCR8 as well as many 
other splicing factors (Gregory R.I et al, 2004). Upon the processing of pri-miRNA 
by the Microprocessor complex, a shorter stem-loop shaped RNAs called 
precursor miRNA (Pre-miRNA) is formed, that is about 70 nt RNAs with 2-3 
nucleotides 3’ overhangs, 25-30 base pair stem containing multiple bulges and 
mismatches  with relatively small loops (Lee Y. et al, 2003). Pre-miRNAs bearing 
a base-paired 5’ end and 3’ overhang of about 3 nucleotides are then transported 
to the cytoplasm by Exportin 5/RAN-GTP complex (Yi et al, 2003; Bohnsack et al 
2004; Gwizdek et al, 2003). 
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Figure 3: microRNA 
processing model:  
microRNA (miRNA) genes are 
transcribed by RNA Polymerase 
II (Pol II) to form large pri-
miRNA transcripts, which are 
capped and polyadenylated. 
These pri-miRNA transcripts are 
processed by the RNase III 
enzyme Drosha and its co-
factor, to release the ~70-
nucleotide pre-miRNA precursor 
product. RAN–GTP and 
exportin 5 transport the pre-
miRNA into the cytoplasm. 
Subsequently, another RNase 
III enzyme, Dicer, processes the 
pre-miRNA to generate a 
transient ~22-nucleotide 
miRNA:miRNA* which will 
eventually result in mature 
single stranded miRNA (Lee Y. 
et al, 2003). 
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In the cytoplasm, pre-miRNAs are cleaved by Dicer, cytoplasmic RNase 
III-type enzyme. Dicer contains two RNase III domains, each domain cuts 
independently one RNA strand of the pre-miRNA complex yielding a product of 
about  22 nucleotides in length with 2-3 nucleotides overhang, during this 
process the duplex is unwound by unknown helicase-like enzyme (Kolb F.A. et 
al, 2005). Subsequently one strand dicer cleaved pre-miRNAs called the mature 
miRNA is incorporated into effecter complexes that are known as ‘miRISC’ 
(miRNA-containing RNA-induced silencing complex) (Hutvagner and Zamore , 
2002). miRISC complex delivers mature miRNA to its target mRNA through base 
pairing with the 3’ untranslated regions (UTR) (Bartel D.P et al., 2004).  
miRNAs control gene expression by binding to the complementary sites in 
the 3′ untranslated regions (3′ UTRs) of target mRNAs (Figure 4), however, the 
target sequence inserted into the 5’UTR or the coding sequences are also 
functional (Kloosterman W. et al, 2004). If the miRNA has perfect or near-perfect 
complementarity to the 3’UTR of target mRNA, it will result in mRNA 
degradations (Figure 4 A) (Hutvagner & Zamore 2002; Bartel D.P et al., 2004). 
On the other hand, the presence of multiple mismatches between miRNA 
sequence and mRNA of target site, leads to translational inhibition without 
affecting mRNA levels of target site (Figure 4 B) (Bartel D.P et al., 2004). 
Molecular mechanism underlying either miRNAs mRNA mediated degradation or 
miRNAs mediated translation repression are not fully understood, thus both 
mechanisms are subject of intense investigation. 
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Figure 4: miRNAs control gene expression: MiRNAs that bind to their mRNA targets 
with perfect complementarity induce target-mRNA cleavage Panel A. The mature miRNA 
binds to complementary sites in the mRNA target to regulate gene expression in one of 
two ways, miRNAs that bind to mRNA targets with imperfect complementarity block 
target gene expression at the level of protein translation Panel B.  
 
1.8 Hsa-mir-488* and Hypothesis: 
 
Recent studies reported that some miRNAs might play an important role in 
prostate cancer by targeting the expression of some growth regulatory genes. 
These miRNAs include miR-15 (Bonci D. et al, 2008), miR-101 (Varambally S. et 
al, 2008), miR-125b (Lee C.Y. et al, 2005), miR-221 (Folini M. et al., 2009). 
Unexpectedly, no miRNA yet to date has been reported to regulate androgen 
receptor in prostate cancer, despite the fact that androgen receptor ablation has 
been found to inhibit cell proliferation, thus demonstrating the essential functional 
role of AR in the growth of prostate cancer cells. We hypothesized that miRNAs 
may be involved in the regulation of androgen receptor signaling and these 
miRNA could be used for targeting androgen receptor in prostate cancer. Using 
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computational analyses, we identified a potential target site for hsa-miR-488* in 
the 3’ untranslated region of androgen receptor mRNA.  
Hsa-miR-488* encoded in intron 5 of Astrotactin 1 (ASTN1) gene (Figure 5). 
Astrotactin is a neuronal adhesion molecule required for glial-guided migration of 
young postmitotic neuroblasts in cortical regions of developing brain, including 
cerebrum, hippocampus, cerebellum, and olfactory bulb (Flink et al, 1995). 
Figure 5: Astrotactin gene host the intronic region that code for Hsa-mir-488*. Hsa-mir-
488* encoded in intron 5 of the ASTN 1 gene.  
This work investigated the methods to validate miR-488* target site in the 
proposed gene (AR). What are some of the effect of miR-488* on its targets in 
prostate cancer cells, and could this technique be used on different target sites? 
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CHAPTER II 
MATERIALS AND METHODS 
 
2.1 Cell Lines and Cell Culture: 
 LNCaP: 
The androgen-dependent human prostate carcinoma cell line LNCaP, was 
obtained from American Type Culture Collection ATCC (Manassas, VA). LNCaP 
cells were cultured in appropriate cell culture grade plates with 1X RPMI 1640 
medium supplemented with 10% Fetal bovine serum (FBS) Atlanta Biologicals, 
Inc. (Lawrenceville, GA) 2mM L-glutamine and antibiotics (100 units/ml of 
penicillin G sodium, 100µg/ml streptomycin sulphate). LNCaP cell lines were 
maintained in a humidified 5% CO2 at 37°C.  
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CHO: 
Chinese Hamster Ovary cell line CHO, was obtained from American Type 
Culture Collection (Manassas, VA). CHO cells were cultured either in 6 well or 24 
well plates with 2 ml or 500µl of Dulbecco’s Modified Eagle’s Medium (DMEM) 
respectively, supplemented with 2 mM L-glutamine, 4.5 g/l Glucose, 5% Fetal 
bovine serum (FBS) Atlanta Biologicals, Inc. (Lawrenceville, GA), 1 mM L-
proline, 10mM HEPES and antibiotics (100 units/ml of penicillin G sodium; 
100µg/ml streptomycin sulphate). Trypsin 1X was added up to 2 ml of cells and 
incubated at room temperature for 3 minutes. Trypsin 1X was quenched with 3 
ml of DMEM 1X supplemented with 5% FBS, 1mM L-proline, 10 mM HEPES and 
antibiotics. Cells were finally seeded at an approximate density of 3.0 x 104 
cells/well for 24 well plates and 1.0 x 105 cells/well for 6 well plates. All cell lines 
were maintained in a humidified 5% CO2 at 37°C.  
2.2 miRNA target validation: 
 
miRNA is an emerging field of since and the knowledge about miRNAs 
target still limited. Researcher in the field of miRNA combined computer 
algorithms with biological information after the establishment of the human 
genome to identify and predict target site for miRNAs. This new field of science is 
called bioinformatic in our lab we have used bioinformatic methods, to identify 
miRNAs which can potentially bind to the 3’ UTR of the AR. Several miRNAs 
target prediction tools such as TargeSCAn, MirSCAN, Find TAR and RNAhybrid  
have identified that hsa-mir-488* could  potentially base-pair with the 3’ UTR of 
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the androgen receptor. Hsa-mir-488* has extended base-pair matching sequence 
to the seed region of the predicted site 10 nucleotide and minimal none 
Watsoncrick base paring (1 G: U). Overall hsa-mir-488* has 80% 
complementarities to the predicted target site suggesting that AR 3’UTR could be 
targeted by hsa-mir-488* (Figure 6). 
 
RNAhybrid – Results (QueryID: bibiserv_1269872147_3730) 
 
 
Figure 6: base pair alignment of AR3’UTR wild type and miR-488*:  seed region 
consist of 10 base pair with perfect complementarity, straight line (I) represent 
Watsoncrick base paring, and (:) represent G:U non watsoncrick interaction. 
 
2.3 Cloning of  3’ UTR AR in pMIR reporter Vector: 
Full length wild type AR 3’UTR: 
Primer name  Primer sequence  
AR 3’ UTR 
forward 
5′-GCGCACTAGTACGTTTACTTATCTTATGCCACGGG-3′ 
                SpeI site 
AR 3’UTR 
reverse 
5′-GCGCAAGCTTGTTTGCTTGTTTTTGTTTTGATTTC-3′ 
                HindIII site 
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For the construction of AR 3′ UTR reporter plasmid, two primers (table 1) AR 3’ 
UTR forward and AR 3’UTR reverse were designed to  introduce SpeI and 
HindIII sites (underlined) at the end of PCR  product of 637 bases fragment of AR 
3′UTR spanning the predicted target site for hsa-miR 488* ( Appendix, Fig 2) . 
Thermodynamic analysis of the primers was conducted using computer 
program: Primer Express (Applied Biosystems, Foster City, CA). The resulting 
primer sets were compared against the entire human genome using NCBI to 
confirm specificity and ensure that the primers flanked hsa-mir-488* target site on 
the androgen receptor 3’UTR. 
 AR 3’UTR with both restriction sites was amplified through PCR 
technique using the following PCR conditions. 
PCR conditions: 
Reagent  Volume  Stock 
5X Buffer  10µl 5x 
Mgcl2 5µl 25 mM 
dNTP 1µl 10 mM 
PCR water 30.5µl  
AR 3’UTR forward Primer 0.5µl 10 µM 
AR 3’UTR reverse Primer 0.5µl 10 µM 
Taq polymerase enzyme  0.5µl 5 units/µl 
human gDNA 2 µl 50ng/µl 
  
Optimized Thermocycler Parameters: 
1. 95 oC   2 minutes 
2. 95 oC  1minute 
3. 55 oC  1minute 
4. 72 oC  30 sec (go to 2 x 30 times)  
5. 72 oC  10minutes 
6. 4 oC  4hours 
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 The resulted PCR product purified and concentrated using ZYMO research DNA 
clean & concentratorTM-25 kit (ZYMO, Orange, CA) following the manufactory 
protocol. After restriction digestion with SpeI and HindIII enzyme, the amplified 
DNA was cloned into the corresponding sites of pMIR-REPORT vector (Ambion, 
Austin, TX) downstream of firefly luciferase gene. The resulting plasmid construct 
WT-3′UTR contains a strong CMV promoter driving a luciferase expression 
cassette (Appendix, Fig 3). 
2.4 Full length Mutated  AR 3’UTR: 
 
Site-directed mutagenesis of the putative target site for hsa-miR-488* in 
WT-3′UTR construct was carried out in order to generate the MUT-3′UTR 
constructs using the Change-IT Multiple Mutation Site Directed Mutagenesis kit 
(USB Corporation, Cleveland, OH). In the first MUT-3′UTR construct, 10 
nucleotides in the seed matching region of the target site were mutated to their 
complementary nucleotides using primer  
5’Phosphate group 
CTTATGCCACGGGAAGAACTCTCACGGAAGATTATCTGGGGAAAT   
The newly generated construct was named AR 3’UTR seed MUT (Figure 7) 
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Figure 7: base pair alignment of AR3’UTR seed MUT and miR-488*:  mutations 
introduce to the first 10 nt of the predicted target site (X) represent no interaction (I) 
represent Watsoncrick base paring, and (:) represent G:U non watsoncrick interaction. 
The second primer was designed to mutate the 5’ half of the putative miR-488* 
site of the AR 3’UTR (Figure 8). 
5’Phosphate group 
CTTATGCCACGGGAAGAACTCTCACGGAAGTAATAGACCCGAAAT 
 
 
Figure 8: base pair alignment of AR3’UTR 5’ MUT and miR-488*:  mutations 
introduce to the 5’ half of the predicted target site (X) represent no interaction (I) 
represent Watsoncrick base paring. 
 
Both of the mutated constructs AR3’UTR seed MUT and AR3’UTR 5’MUT, as 
well as a new construct combining both mutations on the same backbone were  
generated following Change-IT Multiple Mutation Site Directed Mutagenesis kit 
manufacturer protocol. Nucleotide sequences of the constructs were confirmed 
by DNA sequencing. 
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2.5 Construction of vector expressed miR 488* “Pre-miR-488*”: 
 
Segment of 383bp from intron 5 of ASTN 1 gene harboring the precursore 
sequence of miR 488* along with a flanking region was amplified from human 
genomic DNA using the following primers carrying XhoI and BamHI sites (Table 
3). 
 
Primer name  Primer sequence  
Pre-488*  
forward 
5′- GCACCTCGAGTGGGAGTGAGGGAGGCGGGGGAAG-3′ 
                 XhoI 
Pre-488*  
reverse 
5′- GCACGGATCCCCCCCAATCCTTGCCTAGCTCAAAC-3′ 
                 BamHI                 
 
The XhoI-BamHI digested amplified DNA was cloned into the corresponding sites 
in pcDNA 3.1 (-) vector (Invitrogen, Carlsbad, CA). This construct was named 
Pre-miR 488*. The primer validation and cloning method were performed as for 
previous construct (Appendix, Fig 6).  
2.6 Transient Transfection: 
 
 Equal cell numbers (3.0 x 104  cells/well for 24 well plate and 1.0 x 105 
cells/well for 6 well plates)  were seeded twenty four hours prior to transfection  in 
DMEM 1x Supplemented with 2mM L-glutamine, 4.5 g/l Glucose, 5% Fetal 
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bovine serum (FBS) Atlanta Biologicals, Inc. (Lawrenceville, GA ), 1mM L-
proline, 10mM HEPES, but no antibiotics. Two Transfection procedures have 
been used: 
Transfection via lipofictamein 2000:  
This method was used with all transfections with miRNA mimic in 24 well 
plates. Two separate solutions were prepared as following: 
- Solution I: In an Eppendorf tube, 0.75 µl of lipofectamin 2000/well was 
added to 50 µl of free serum free P/S CHO media. After gentle mixing 
through pipetting, the solution was incubated at room temperature for 5 
min. 
- Solution II: In an Eppendorf tube, 100 ng of AR 3’UTR firefly luciferase 
reporter construct was added to 50µl of free serum free P/S CHO 
media and then mixed with 0.5 ng of Renilla luciferase reporter 
plasmid. Finally, 10 nM of miR-488* mimic was added to the mixture. A 
Negative Control for the microRNA (NC mimic) was also prepared by 
adding 10nM of NC mimic to the mixture instead of miR-488* mimic.  
Solution I and Solution II were mixed gently three to four times by pipetting and 
then incubated at Room temperature for 20 minutes.  
The total volume of 100 µl of Transfection mixture (Solution I + Solution II) was 
added drop by drop to the corresponding labeled wells which already contain 
500µl of DMEM 1X supplemented with 2 mM L-glutamine, 4.5 g/l Glucose, 5% 
Fetal bovine serum (FBS) Atlanta Biologicals, Inc. (Lawrenceville, GA ), 1mM L-
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proline, 10mM HEPES, but no antibiotics . The 24 well transfected plate was 
incubated in a humidified 5% CO2 incubator at 37°C for 48 hours.  
Transfection via polyBrene:  
This method was used to transfect CHO cells with Pre-miR-488* construct 
in 24 well plates. In an Eppendorf tube, 1.5 µl of PolyBrene10µg/µl was added to 
500µl of free P/S CHO media.  After mixing the required amount of PolyBrene 
and free P/s media, the required concentrations of Pre-miR-488* was added. 100 
ng of AR 3’UTR firefly luciferase reporter construct was added to the previous 
solution and then mixed with 0.5ng of Renilla luciferase reporter plasmid. Finally 
the mixture was incubated at room temperature for 5 min. Meanwhile the CHO 
medium was aspirated from the wells and the previously prepared transfection 
mixture was added to the designated wells. For the followed eight hours, the 
transfected plates were maintained in a humidified 5% CO2 atmosphere at 37°C 
incubator with gentle swirling every one hour.  Eight hours later, the Transfection 
media was aspirated out of the wells and the DMSO (Dimethyl Sulfoxide) shock 
was performed by adding 500 µl of 30% DMSO/ CHO media. The cells were 
incubated in the Shock medium at room temperature for 5 minutes. A washing 
step using 500 µl of CHO complete media was done, and then another 500µl of 
freshly prepared CHO media was added to each well.  Finally, the transfected 
plates were maintained in a humidified 5% CO2 atmosphere at 37°C incubator for 
fourty eight hours from DMSO shock point. 
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2.7 RNA  Extraction: 
 
Total RNA from experimental and control wells were isolated from 80% 
confluent cells directly in the 6 well culture plate. Cells were homogenized in the 
culture dish and lysed directly by adding 1 ml of TRIZOL® Reagent (Invitrogen, 
Carlsbad, CA) following manufactor’s protocol. The cell lyzate was collected in 
1.5 ml Eppendorf tube. Samples were treated with chloroform, incubated at room 
temperature for 2 to 3 minutes and centrifuged (12,000 x rpm) for 15 minutes at 4 
°C. The upper aqueous phase (approximately 450µl) was transferred to a fresh 
tube and precipitated by adding 1 volume of isopropanol to extract RNA. After 10 
minutes of incubation at room temperature, RNA pellet was collected by 
centrifugation (12,000 rpm) for 10 minutes at 4° C. After discarding the 
supernatant, RNA pellets were washed with 1 ml 75% ethanol/ DEPC water and 
precipitated by centrifugation (12,000 rpm) for 5 minutes at 4°C. Pellets were 
resuspended in 50 µl of Rnase-free water. RNA yield and purity were determined 
spectrophotometrically at 260-280nm and the reliability of RNA was verified by 
electrophoresis through 1 % denaturing agarose gels stained with ethidium 
bromide. 
2.8 Protein Extraction: 
 
 Additional wells containing experimental and control CHO cells were 
seeded for protein extraction. Cells were washed once with 500 µl cold PBS in 24 
well plates. 100 µl of 1X passive lysis Buffer (PLB) was added and the culture 
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dish was gently rocked for 45 minutes at RT, then homogenized materials were 
collected in microcentrifuge tubes. Slow centrifugation at 4000 rpm for 15 
minutes at 4° C was performed to pellet down any unlysed cells. The Protein 
quantification was determined by spectrophotometry at 595 nm and using 1X 
Bradford reagent (Bio-Rad Hercules, CA). The total protein concentration was 
calculated. Total protein lysates were stored at -80° C for further experimentation 
procedures.  
2.9 Dual Luciferase assay: 
 
For Dual luciferase assays, CHO cells (30,000 cells/ well) were plated in 
24-well plates one day prior to transfection. Cells were co-transfected using 
lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA), with 100 ng of WT-3′UTR 
or MUT-3′UTR firefly luciferase reporter construct, 0.5 ng of renilla luciferase 
reporter plasmid and either miR 488* mimic (10 nM) or NC mimic (10 nM).  Cells 
were harvested and total protein concentrations were determined by Bradford 
method 48 hours after transfection. 10 µg of total cell protein lysates were 
assayed for firefly and Renilla luciferase activities using the Dual-Luciferase 
Reporter Assay System (Promega, Madison, WI) and Victor 3 Multilabel Counter 
1420 (PerkinElmer). Aliquots of 10 µg of total cell protein lysates were transferred 
into oblique 96 well plates and 100 µl of LAR II reagent (Promega, Madison, WI) 
was dispensed into each well followed by orbital shaking for 2 seconds and 
incubation time of another 2 seconds, then 10 seconds of measurement of the 
emission light produced from the fire fly luciferase. Reading was recorded 
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electronically. In order to quinch the emitted light from the firefly luciferase and to 
activate the emission of light from Renilla luciferase, 100 µl of Stop & Glo® 
reagent (Promega, Madison, WI) was added to the previous wells, followed as 
before by 2 second of orbital shaking and 2 second of incubation time, then 10 
second of measurement of emission of light produced by Renilla luciferase. 
Readings were recorded electronically. The whole procedure was carried out at 
room temperature.  
2.10 Quantitative Real-Time (qRT) PCR Analysis of Mature miRNA 
Expression: 
 
From 10 ng of total RNA the first strand cDNA was synthesized using 
primers specific for miR-488* and snoRNA 202. Both primers were obtained from 
TaqMan MicroRNA Assays (Applied Biosystems Foster City, CA). Reagents for 
cDNA synthesis were obtained from TaqMan MicroRNA Reverse Transcription 
kit (Applied Biosystems). For each sample, a 15µl reverse transcription (RT) 
reaction was set up containing 10ng of total RNA, 1X RT buffer, 1mM of dNTP 
mix, 50 units of MultiScribe reverse trancriptase, 3.8 units of RNase inhibitor and 
3µl of miRNA-specific RT primer. The reactions were incubated in a thermal 
cycler (BIORAD PTC-100) at 16°C for 30 minutes, 42° C for 30 minutes, 85° C 
for 5 minutes and then held at 4°C. The ‘reverse transcriptase minus’ controls 
were also synthesized under the same conditions. In order to quantify the mature 
miRNAs and snoRNA 202 in each sample, the cDNAs were amplified using 
TaqMan MicroRNA Assays together with the TaqMan 2X Universal PCR Master 
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Mix (Applied Biosystems Foster City, CA). For this step, a 20µl reaction was set 
up containing 1.33 µl product from RT reaction, 1µl of 20X TaqMan microRNA 
assay mix (mixture of miRNA-specific forward and reverse primers, and miRNA-
specific TaqMan MGB probe labeled with FAM fluorescent dye) and 10 µl of 
TaqMan 2X Universal PCR Master Mix. These reactions were dispensed into a 
96 well optical plate (Applied Biosystems Foster City, Ca). The plate was 
centrifuged at 2000 rpm for 5 minutes to remove any air bubbles that might be 
formed. After insuring the absence of air bubbles, the plate was positioned in 
7500 Real-time PCR System (Applied Biosystems) under the following 
conditions: 95°C for 10 minutes followed by 50 cycles of 95°C for 15 seconds 
and 60°C for 1 minute. Three replicates were performed per RT reaction together 
with the ‘reverse transcriptase minus’ and ‘no template’ controls. Duplicate PCRs 
were performed for all miRNAs in each RNA sample. The mean Ct was 
determined from the replicates. The snoRNA 202 expression was used as an 
invariant control. The relative expression of each miRNA was calculated as 2-ΔCt 
where ΔCt = Ct value of each miRNA in a sample – Ct value of snoRNA 202 in 
that sample. All experiments were repeated at least twice with three replicates 
and two independent RNA samples (Appendix, Fig 7).  
2.11 Statistical analysis: 
 
To interpret our results, significance tests and statistical analysis are critical. 
The traditional α-value, i.e., p = 0.05, was used to evaluate the statistical 
significance of this study. The data of the dual luciferase and q-RT-PCR assays 
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results  will be expressed as the mean ± SEM and compared using student's t-
test for normally distributed samples.  The results were analyzed using the 
MYSTAT 12 version 12.02.00 statistical program (Systat Software, Inc.Chicago, 
IL) and Microsoft Excel (Microsoft, Seattle, WA). The index of expression of each 
miRNA was 2-ΔCt after normalization to snoRNA 202 expression levels. Hence, 
results were considered statistically significant if p values were < 0.05.  
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CHAPTER III 
RESULTS and DISCUSSION 
 
3.1 Identifying potential target site for miR-488* in AR 3’UTR: 
 
 
Androgen receptor (AR) plays a central role in the development and 
progression of prostate cancer in humans. AR is heterogeneously expressed in 
primary tumors and throughout the progression of androgen dependent and 
androgen independent “hormone-refractory prostate cancers”.  Prostate cancer 
initiates as an androgen-dependent disease, and further accumulation of multiple 
sequential genetic and epigenetic alterations transform it into an aggressive, 
therapy resistant, androgen-independent prostate cancer (AIPC).  
The molecular basis of the transition from androgen dependent to AIPC is still 
unclear however; recent studies suggest that hypersensitivity of AR to trace level 
androgens combined with androgen ablation therapy could provide a selective 
pressure on the cellular pathways which are regulated by androgen signaling 
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(Taplin, N.E et al, 1999; Craft N. et al, 1999). Consequently, androgen dependent 
cancer cells adapt to the androgen-deprived conditions and furthermore select 
mutated AR that is able to utilize an anti-androgen antagonist as an agonist for 
their aggressive growth and proliferation (Marques, R.B et al, 2005). 
 
MicroRNAs molecules can regulate gene expression in many different 
organisms by functioning as negative gene regulators (lee et al, 1993; lee and 
Ambrose, 2001; Bartel, 2004; Pasquinelli et al, 2000). In order to study the effect 
of  miRNAs on AR, we 
had to identify one 
miRNA that has the 
potential to bind to the 3’ 
untranslated region of 
androgen receptor. 
Bioinformatic programs 
such as TargeSCAN, 
MirSCAN, Find TAR and 
RNAhybrid aided in 
accomplishing this task 
by predicting one target site in the AR 3’UTR. 
 Our bioinformatics results indicated that hsa-mir-488* has target site in the 3’ 
UTR of AR. Base pair interaction between the predicted target site and hsa-mir-
488* is shown in (Figure 9). 
Figure 9: Schematic representation of AR 3’UTR with
the location of miR-488* predicted target site: Hsa-
miR-488*  has extended seed region complementarity to
the predicted target site ( 10 bases ), followed by three 
bulges, resulting in 80% complementarity to the target 
site, according to Bartel et. al this such interaction should
result in translation repression but not mRNA
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Furthermore, bioinformatics approaches showed that the predicted target site 
is evolutionary conserved across different species (Figure 10).  Those similarities 
in sequence alignment serve as evidence for structural and functional 
conservation, thus this predicted site might have an important function within the 
development of these species.   
In addition, precursor sequence for hsa-miR-488* encoded in intron 5 of 
Astrotactin 1(ASTN1) gene in human is also highly conserved in five species 
(Figure 11). This is a further evidence that miR-488* has an evolutionary 
conserved role within the lineage of evolution. This extensive conservation 
strongly indicates a more general role for hsa-miR-488* in developmental 
regulation, as well as the predicted target site to be an authentic target site. 
Figure 10: Cluster alignment of AR 3’UTR of different species: Sequence alignment 
of the miR-488* putative predicted target site in the AR 3’UTR of five different species: 
Target site boxed in green and stars indicate the conservation across all five species. 
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3.2 Effect of miR-488* on AR expression: 
 
In order to experimentally test the potential of miR-488* to regulate the 
expression of AR, my lab 
colleague Dr. Sikand 
transfected PCa 
Hormone dependent cell 
line (LNCaP) with miR-
488* mimic or negative 
control (NC), negative 
control being a miRNA 
from C. elegance that 
has no target site in 
human genome. After 48 
hours of transfection, 
cells were collected and 
total protein amount was estimated, then a western blot was performed in order 
to determine the AR protein expression. β-Actin was used as an internal control. 
Figure 12: Effects of miR-488* mimic on AR protein 
expression: LNCaP cells were transfected with either 
miR-488* or NC mimic with the appropriate controls, cells
were collected after 48 hours, total protein estimation was
performed followed by western blot analysis. Results
indicate high reduction of AR protein levels when
transfected with miR-488* mimic compared to cells
transfected with either NC mimic or mock transfected. 
Figure 11: Cluster alignment of precursor sequence of miR-488* in five different 
species: Sequence alignment of pre-miR-488* in five different species, miR-488* mature 
sequence in red box. Stars indicate the conserved nucleotides. 
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Results are shown in (Figure 12): when cells were transfected with different 
concentration of miR-488* mimic, a high reduction of AR protein levels was 
observed comparing to the cells transfected with the same concentrations of 
negative control miR mimic. In addition,  negative control mimic had no effect on 
the AR levels compared to no transfection or mock transfection, which clearly 
indicates that the change in AR protein levels is due to the effect of miR-488* on 
the expression levels of Androgen receptor protein. Transient transfection of miR 
488* mimic resulted in robust suppression of AR protein expression in LNCaP 
cells. 
3.3 Target Validation: Construction of Luciferase Reporter Plasmids 
expressing AR 3’UTR. 
 
In order to validate the previously observed 
data, we have to demonstrate that the repression 
of AR protein is due to the interaction between the 
predicted AR mRNA target site and miR-488*. To 
address this question, we cloned the AR 3’UTR 
containing the putative wild type miR-488* target 
site into the 3' multiple-cloning-site (MCS) of 
pMIR-REPORT vector (Ambion, Austin, TX) 
downstream of firefly luciferase gene as described 
in the “materials and method” section. The 
resulting plasmid construct WT-3′UTR contains a 
strong CMV promoter driving a luciferase 
Figure 13: Restriction
digestion clone confirmation:
AR 3’UTR clone was confirmed
by double digestion with SpeI
and HindIII enzyme and
analyzed on 1 % agarose gel. 
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expression cassette (Appendix, Fig 3). The resulted clones first were confirmed 
by double digestion with SpeI and HindIII enzyme and analyzed on 1 % agarose 
1X TAE gel and compared to 1 Kb ladder (Figure 13). As expected, a fragment of 
637 base pair product was observed in two clones (clone #2 and clone # 8) 
indicating that AR 3’UTR was cloned successfully into the MCS of pMIR-
REPORT. For further confirmation, the resulted clones were sequenced in the 
Cleveland clinic foundation genomic core facility, and once again the sequence 
result proved that indeed the cloned fragment is the AR 3’UTR. 
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3.4 Target Validation: Effect of miR-488* mimic on the chimeric  AR 3’UTR  
WT luciferase reporter plasmid: 
 
To address if miR-488* could target the AR 3’UTR, we have transfected 
the resulted chimeric sensor plasmid along with Renilla luciferase plasmid 
and the appropriate controls as described in the materials and method section 
into 80 % overnight grown CHO cells in the absence of antibiotics using 
lipofectamine 2000 as transfection reagent of choice. After 48 hours post 
transfection, cells were 
collected, washed once with 
1X PBS and lysed in 1X PLB. 
Total protein was estimated 
using Bradford reagent and 10 
µg of total protein was loaded 
into the designated wells of 
the 96 well plates. Protein 
lysates were assayed for 
firefly and Renilla luciferase 
activities using the Dual-
Luciferase Reporter Assay 
System (Promega, Madison, 
WI) and Victor 3 Multilabel 
Counter 1420 (PerkinElmer).  
Figure 14: Quantitative analysis of the chimeric
AR 3’UTR wild type luciferase plasmid repression
by miR-488* mimic: CHO cells were cotransfected
with chimeric AR 3’UTR luciferase reporter plasmid
along with Renilla luciferase plasmid and miR-488*
mimic (10nM) or NC mimic (10nM) are indicated.
Down regulation of 51% of the firefly luciferase when
transfectecd with miR-488* mimic was observed
compared to transfection with NC. 
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 Results showed that the transfection of miR-488* along with chimeric 
sensor plasmid (AR 3’UTR) resulted in down regulation of about 51% comparing 
to transfection with negative control of the same concentrations. This result 
indicates that miR-488* might be interacting and negatively down regulating the 
AR 3’UTR chimeric plasmid. However we are certain that this result is due to the 
interaction of miR-488* with the predicted target site and not with the body of 
pmiR REPORT, since no down regulation was observed when pmiR REPORT 
empty vector was transfected with the same concentration of miR-488* mimic 
and NC mimic. Furthermore none of the microRNAs target prediction tools have 
shown any target site for miR-488* in the empty pMIR report vector. 
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3.5 Base pair interaction between miR-488* and predicted  target site: 
 
MicroRNAs mediate gene expression through translational repression of its 
target mRNA by binding to the 3’ untranslated region (UTR) in imperfect 
complementarity (Wightman B. et al, 1991; Bartel, 2004). MiR-488* has 80% 
complementarity to the predicted site, thus it is believed to bind to the predicted 
target site and through an ambiguous and not fully understood mechanism, drive 
an expression repression of its target gene (Nilsen T, 2007). To validate if miR-
488* is directly 
interacting with the 
predicted target site, 
a new construct 
harboring the AR 
3’UTR with mutated 
seed region (first 10 
nucleotides from 3’ 
end of the predicted 
target site) to its 
complementary 
nucleotides was generated as described in “Materials and Method” chapter II. 
Furthermore, a construct with the 5’ half of the predicted target site (bulge region) 
was mutated to its complementary nucleotides. In addition, another construct 
harboring both of the previously mentioned mutations within the same target 
(Figure 15) was designed and generated. The first construct with seed mutations 
Figure 15: Base pairing interaction between miR-488* and
predicted target site: Three constructs were generated, first
one harboring mutated seed region, second with mutated bulge
region and third with mutated seed region as well as mutated
bulge region. 
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was named AR 3’UTR seed MUT; the second construct with bulge mutations 
was named AR 3’UTR 5’ MUT and the final construct harboring seed mutations 
as well as bulge mutations was named AR 3’UTR 3’/5’ MUT.  
The three mutations were transiently co-transfected into CHO cells with miR-
488* mimic and NC mimic as well as renilla luciferase construct as a transfection 
control with all the appropriate controls. Results are shown in (Figure 16). When 
cells were transfected with the wild type AR3’UTR chimeric plasmid along with 
miR-488* mimic, results were similar to previously obtained with repression of 
luciferase expression of about 55% compared to transfection with NC mimic 
(Figure 16A).   
On the other hand, the co-transfection of the AR 3’UTR seed MUT chimeric 
plasmid along with miR-488* mimic resulted in down regulation of about 33% 
compared to NC mimic transfection (Figure 16B). A down regulation of about 
58% of luciferase expression was observed when cells were co-transfected with 
AR 3’UTR 5’MUT along with miR-488* compared to NC mimic (Figure 16C). 
Unexpectedly, 45 % reduction of luciferase activity was observed when cells 
were co-transfected with AR 3’ UTR 3’/5’ MUT with miR-488* mimic compared to 
NC mimic (Figure 16D).  
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Figure 16: Effect of AR 3’UTR mutations on the levels of luciferase expression in
the chimeric plasmid: CHO cells were co-transfected with either wild type AR 3’UTR
chimeric plasmid or mutated: Panel A, 55% reduction of luciferase expression was
observed when transfected with WT AR 3’UTR and miR-488* mimic. Panel B 33%
reduction of luciferase expression was observed when transfected with AR 3’UTR seed
MUT and miR-488* mimic. Panel C, 57% reduction of luciferase expression was
observed when transfected with AR 3’UTR5’ MUT and miR-488* mimic. Panel D, 45 %
reduction of luciferase expression was observed when transfected with WT AR 3’UTR
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Results from panel B and C compared to Panel A, suggest the seed region 
seems to play a major role in the interaction between the miR-488* and the 
predicted site in the AR 3’UTR. Nevertheless, results from Panel A and Panel D 
suggest that there might be other putative sites within the AR 3’UTR mRNA 
which can interact with miR mimic by Base-pairing. Presumably, these sites are 
providing miR-488* mimic with substitutionally binding segments, when the first 
original site (nucleotides 4266-4289) of the AR 3’UTR is mutated. Hence, the 
down regulation of luciferase expression was still observed even with mutations 
designed to interrupt interaction between miR-488* and the predicted target site. 
3.6 Cloning Shorter AR 3’ UTR: 
 
Next question we asked is: Are there any sites that miR-488* is binding to 
other than the putative site (nucleotides 4266 – 4289)?  To address this question, 
careful observation of the Wild type AR 3’UTR sequence revealed the identity of 
three sites which might serve as substitution binding sites (Appendix; Fig 4A). 
Site one (nucleotides 158-168 from 5’ end of AR 3’UTR) is consisting of 10 
nucleotides with 7 perfect matches to the seed region. Site two (nucleotides 293-
299 from 5’ end of AR 3’UTR) has 6 nucleotides with 4 perfect matches to the 
seed region and site three (nucleotides 348-358 from 5’ end of AR 3’UTR) is 10 
nucleotides with 8 perfect matches to the seed region (Appendix; Fig 4B). 
Mutation Site Directed Mutagenesis kit (USB Corporation, Cleveland, OH) was 
used as described in Chapter II, Section 2.4 to individually mutate each newly 
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revealed sites. Resulted constructs with either mutations in Site I, II or III were 
co-transfected individually with miR-488* mimic and the appropriate controls. 
Data showed similar repression levels of fire fly luciferase ( 54 %, 53% and 52% ) 
for mutated site one, mutated site two and mutated site three, respectively as 
compared to WT AR 3’UTR with 51% fire fly luciferase repression( Appendix; Fig 
5). 
These results did not explain neither proves if site one, two and three could 
serve as substitution binding site for miR-488*. Since we did not have one 
construct harboring all 
mutated sites as well as 
the mutated seed region 
in the putative target site, 
we decided to clone a 
shorter segment of AR 
3’UTR (nucleotides 561-
637 from 5’ end of AR 
3’UTR (Appendix: Fig 4A & 4B). This segment (77 nucleotides) of AR 3 UTR 
contained the wild type (Short AR WT) or seed mutated miR-488* target site 
(Short AR seed MUT) in a luciferase reporter vector. For the following set of 
experiments a new negative control (miR-488* mut mimic). This new control 
harboring 4 mutated nucleotides to its complementary bases in the seed region 
(Figure 17). miR-488* mut mimic was used along with the old negative control 
from C. elegans.  
Figure 17: miR-488* mutated mimic alignment
with AR 3’UTR:  miR-488* mutated mimic; this new
negative control have the same nucleotides as miR-488*
but with 4 nucleotides to be mutated to its complementary
bases in the seed region. Mutated nucleotides are
indicated in blue color in seed region. 
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Each of these constructs was co-transfected with either miR-488* mimic or 
negative control mimic in CHO cells and luciferase activity was measured after 
48 hours.  
miR-488* reduced luciferase activity of the Short AR WT construct by 30%     
as compared to that with the NC mimic and miR-488* mut mimic. However, in 
CHO cells transfected with Short AR seed mut chimeric luciferase reporter 
plasmid, miR-488* was unable to suppress luciferase activity. Luciferase 
expression in these cells was similar to that seen in cells co-transfected with 
Short AR seed mut construct and either NC mimic or miR-488* mut mimic 
(Figure 18). 
 
Figure 18: Chimeric plasmid with Shorter AR 3’UTR can be targeted by miR-
488*: Mir-488* reduced luciferase activity of the Short AR WT construct by 30% as
compared to that with the NC mimic and miR-488* mut mimic. In CHO cells
transfected with Short AR seed mut, chimeric luciferase reporter plasmid, miR-488*
was unable to suppress luciferase activity. Luciferase expression in these cells was
similar to that seen in cells co-transfected with Short AR seed mut construct and
either NC mimic or miR-488* 
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These data suggest that miR-488* putative target site within the shorter AR 
3’UTR seems to be an authentic site. Also the reversal of luciferase expression 
by miR-488* mut mimic suggests that only four nucleotides mutations in the seed 
region are sufficient enough to disrupt the interaction between miR-488* mimic 
and predicted target site which is consistent with the common line of thoughts for 
microRNA mediated gene regulation (Nilsen T, 2007). 
 
3.7 Dose dependent expression of mature miR-488* from Pre-miR-488* 
expression plasmid: 
To study the 
effects of hsa-miR-488* 
expressed from its 
genomic context, an 
expression reporter 
system which could 
experimentally enable us 
to express the mature 
form of miR-488* and 
study its effects was required. To achieve this aim, a segment of intron five in 
ASTN1 gene was PCR amplified from human genomic DNA and cloned between 
XhoI and BamHI sites of pcDNA 3.1(-) under the expression of CMV promoter. 
The cloned segment of intron 5 from ASTN 1 gene, codes for hsa-miR-488* 
Figure 19:  Quantitative Real-Time (qRT) PCR
analysis of mature miR-488* expression: An increased
dose dependent expression of mature miR-488* was
observed respectively to increased concentration of
transfected pre-miR-488* chimeric expression vector. 
 47 
 
precursor, along with both downstream and upstream flanking regions (Appendix; 
Fig 6). This construct was named Pre-miR-488*. Overnight grown, 80 % 
confluent Chinese Hamster Ovary cells were transfected with different 
concentrations of Pre-miR-488* construct, using polybrene as transfection 
reagent as described in materials and method. Cells were collected and total 
RNA was extracted by mean of TRIZOL® Reagent. Quantitative real time PCR 
technique was used to assess in detecting the mature miR-488* in total RNA 
aliquots of 10 ng from each transfected concentration samples. 
As expected no endogenous expression of miR-488* was detected in 
untransfected samples. However, samples transfected with increased 
concentration of pre-miR-488* (1.5, 2.0 and 2.5 µg) showed an increased 
expression profiles respectively to amount of transfected plasmid expressing 
genomic miR-488* gene (Figure 19). Cells transfected with 2.5 µg pre-miR-488* 
expressed mature miR-488* by about 2 fold higher than those transfected with 
1.5 µg. These results suggests a dose dependent expression of miR-488* gene 
in transiently transfected mammalian cells. 
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3.8 Dose dependent repression of Firefly luciferase expression by Pre-miR-
488* : 
 
We have shown that synthetic miR-488* could down regulate the expression 
of the chimeric luciferase reporter plasmid. Next we investigated whether miR-
488* gene can also repress the luciferase activity from the chimeric AR 3’UTR 
plasmid. 
To address this question, we transfected CHO cells with Short AR 3’UTR wild 
type plasmid and short AR seed MUT plasmid along with increased 
concentration of the pre-miR-488* expression plasmid. As for controls we 
transfected a pool of the cells with empty expression plasmid (pcDNA 3.1 ) and 
Renilla luciferase plasmid served as internal control for transfection. As shown in 
Figure 19, Dual luciferase assay’s results of samples transfected with increased 
concentrations of pre-miR-488* (1.5µg, 2.0µg and 2.5µg) have indicated a 
reduction of luciferase activity of about (10 %, 20 % and 27 %) respectively, to 
transfected concentration. However the sample of cells transfected with Short AR 
seed MUT show reversal of luciferase expression similar to results obtained from 
sample transfected with the empty expression vector. Results were normalized to 
Renilla expression and represented in (Figure 20). 
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Figure 20: Quantitative analysis of repression of luciferase sensor by Pre-miR-488* 
expression vector: Luciferase and Renilla expression was measured with increased 
concentration of transfected pre-miR-488* and with the highest concentration of pcDNA 3.1 
empty vector along with the appropriate controls. All expression values and ratio of Firefly to 
Renilla luciferase were plotted as a measurement of the translational repression of firefly 
luciferase by ectopically expressed mature miR-488*.   
These results were consistent with, observation from induction with 
synthetic miR-488*. Thus, miR-488* gene expressed from its genomic context 
have the same ability to target AR 3’UTR and repress the luciferase activity in the 
chimeric plasmid. miR-488* gene expression profile (Section 3.7) show increased 
levels of mature miR-488* expression respectively, to increased concentration of 
transfected pre-miR-488*. Current data (Figure 20) once again enhance the 
previous observation. The higher the concentration of transfected pre-miR-488*, 
the higher is the concentration of the expressed mature miR-488*. These results 
suggest a negative correlation between the amount of transfected pre-miR-488* 
and the luciferase expression profiles. 
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3.9 Mutations within miR-488* precursor in different cell lines: 
 
Recent studies indicated that miR-488* predominantly  expressed in adrenal 
gland, adrenal cortex and mainly in brain tissues (Wang E, et al. 2009; Landgraf 
P et al. 2007).However, we are not aware of any report linking miR-488* to 
prostate cancer, thus we wanted to explorer wither miR-488* is expressed in 
prostate cells.  Unpublished data by our lab have shown that miR-488* is 
expressed at significantly low levels in androgen dependent cell line (LNCaP) 
and similar results for the androgen independent cell line (C4-2B). However, no 
signal for miR-488* was detected from androgen independent cell line DU145. 
To further investigate these findings, both Forward and Reverse Pre-488* 
primers shown in (Table 3; Chapter II) are great tools to perform PCR on 
genomic DNA collected from several androgen dependent prostate cancer cell 
line (LNCaP), androgen independent prostate cancer cell lines (DU145, PC3, 
and CWR 22RV1), Brain tumor cell lines (U-87 and U251) and Human breast 
adenocarcinoma cell line (MDA). Amplified segments were sequenced and 
analyized by clustral alignement  in (Figure 21), along with the precursore 
sequence for Hsa-miR-488*. 
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Interestingly, all cell lines show high conservation in stem loop region of hsa-
miR-488*, with only one 
point mutation in DU145 
cells. This androgen 
independent cell line 
incorporated a C to G 
substitution in nucleiotids 
60. Interistingly, when both 
wild type miR-488* stem 
loop and the corresponded 
stem loop from DU145 cells 
(CG mutation at base 60) 
folded using RNA-Fold 
program, it revealed different 
structure (Figure 22).  
It has been proposed that RNA:RNA interactions or RNA:protein interaction 
are involved in  structure recognition and processing precursor miRNA to mature 
Figure 21: Cluster alignement of miR-488* stem-loop region in different cell lines: sequence 
alignment of the stem loop region of miR-488* from androgen dependent prostate cancer cell line 
(LNCaP), androgen independent prostate cancer cell lines (DU145, PC3, and CWR 22RV1), Brain 
tumor cell lines (U-87 and U251) and Human breast adenocarcinoma cell line (MDA). 
Figure 22: Folding state of miR-488* stem loop: this 
figure illustrate both folding state of wild type miR-488* stem 
loop and the corspondend stem loop from DU145 cells (CG 
mutation at base 60) 
 52 
 
sequence (Kim et al , 2007). These results along with the mature miR-488* 
expression profile might suggest that the CG mutaion at base 60 in DU145 
contrbute to reduced expression of mature miR-488* in DU145 cell line. 
Nevertheless, further study is required for better understanding for the role of the 
CG substitution in the preocessing of miR-488*. 
3.10 Stable cell line (LNCaP and C4-2B) expressing miR-488*: 
 
Androgens stimulate proliferation and inhibit apoptosis, thus maintain the ratio 
of proliferating cells to those dying. The maintenance of this ratio is very critical 
for the normal growth of prostate cells (Feldman and Feldman, 2001). In prostate 
cancer cells this ratio favoring the proliferation. Additionally, AR is required for 
the proliferation of prostate cells (Feldman & Feldman, 2001; Balk, 2002). 
However, we have shown in this study that AR is a direct target of miR-488*.  
Thus, by stably transfecting miR-488* into prostate cancer cells can we once 
again balance the ratio between proliferation and apoptosis?  
To address this question, plasmid DNA Pre-miR-488* was linearized with 
restriction enzyme, Bgl II and stably transfected into either androgen dependent 
cell line (LNCaP) or androgen independent cell line (C4-2B). Stably transfected 
cells were maintained in RPMI 1640 medium supplemented with 10% Fetal 
bovine serum (FBS), with antibiotics and 100 µg/ml G-148.  
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This selection media allows for only cells expressing the resisting gene 
which is incorporated in Pr-miR-488* plasmid to survive.  All cell lines were 
maintained in a humidified 5% CO2 at 37°C. An interesting observation, that 
LNCaP cells (androgen dependent) did not grow well and number of cells were 
low. While C4-2B cells continued to grow and higher number of cells was 
observed. These results may suggest that more cells are dying to these 
proliferating in the stably transfect LNCaP cells. On the other hand, it seems that 
more cells are proliferating to these dying in the C4-2B (androgen independent 
cell line).  We cannot draw a conclusion whether this phenotype is due to the 
Figure 23: Stable cell line (LNCaP and C4-2B) expressing miR-488*: Panel A, Untransfected
LNCaP cells, Panel B, stably transfected LNCaP cells with Pre-miR-488*. Panel C, untransfected
C4-2B cells. Panel D, stably transfected C4-2B cells with Pre-miR-488*. 
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effect of miR-488* on androgen receptor or not. Further more study is required to 
enhance our understanding of these two phenotypes. 
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CHAPTER IV 
FUTURE DIRECTIONS AND CONCLUSION 
 
4.1 Implication of the CG substitution in mature miR-488* processing: 
 
It has been proposed that RNA:RNA interactions or RNA:protein 
interaction are involved in  structure recognition and processing precursor miRNA 
to mature sequence (Kim et al , 2007). MiRNA processing is a 
compartmentalized process; precursor miRNA at first is made in the nucleus, 
then it is processed into the mature miRNA in the cytoplasm. In order to study 
whether the observed CG mutant in DU145 cells is affecting the nuclear process 
of miRNA precursor or the cytoplasmic process of miRNA maturation; an in vitro 
system could be used where the precursor sequence for miR-488* is cloned 
downstream of T7 promoter in one construct. Second construct harboring the 
precursor sequence for miR-488* along with the observed CG mutation at the 
indicated position (nucleotide 60) will be cloned downstream of T7 promoter.  
 56 
 
After radiolabeling both constructs, they could be used for in vitro miRNA 
processing system with total cellular extract from DU145 cells or LNCaP cells.  
Unpublished data by our lab have shown that miR-488* is expressed at 
significantly low levels in androgen dependent cell line (LNCaP). However, no 
signal for miR-488* was detected from androgen independent cell line DU145. 
These results indicate that the miRNA processing machinery is functional to 
some degree in LNCaP cells but not in DU145. Thus results from the proposed 
experiment ( see above) with the total cellular  extract from LNCaP or  DU145 
cell lines, could give us some insight whether what is observed from mature miR-
488* expression profiles is due to the inactivation of the miRNA processing 
machinery in DU145 cells or is just simply due to the CG substitution.   These 
experiments may provide an opportunity to identify RNA binding proteins unique 
to miR-488* stem loop processing. 
4.2 Identifying miR-488* precursor promoter: 
 
Hsa-miR-488* is encoded in intron 5 of Astrotactin 1(ASTN1). Intron 5 is a 
relatively large intron (4.9 kb) gene (Figure 24). 
 
Figure 24: Schematic presentation of the genomic location of miR-488*: MiR-488* is hosted 
by intron 5 of ASTN 1 gene and preceded by Exon 5, Intron 4 and Exon 4.  
Intronic microRNAs studies suggested that microRNAs that reside in 
introns, share the same promoters and regulatory elements of their host gene  
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(Sikand et al., 2009). 
Nevertheless, other 
miRNA genes are 
believed to be 
transcribed from their 
own promoters. Few 
primary transcripts 
have been entirely 
identified (Lagos-
Quintana et al., 2001; Bartel D P., 2001). Thus to truly understand whether miR-
488* has its own promoter or shares the same promoter of its host gene, we 
could clone the mini gene system harboring Exon4, intron 4, Exon 5 and the 
segment of intron 5 up to the start of the precursor sequence of miR-488* in the 
promoterless pGL 4.20 luciferase vector plasmid (Figure 25). Consequently, after 
transfection of the resulted plasmid into one of the cell lines which previously has 
shown some levels of endogenous  mature miR-488* profiles,  we could assay 
for luciferase activity. The detection of a luciferase activity could mean that the 
mini gene system is harboring a promoter region. Then, we could identify that 
specific promoter sequence together along any transcription factors docking sites 
nearby. 
The promoter sequence, if present, could be identified through truncation 
process of the promoter region. Transcription factor’s docking sites, also if 
present, could be first identified by prediction software’s followed by experimental 
Figure 25: mini gene construct to check for independent 
promoter activity of miR-488*:  including what we think to harbor 
coding sequence for promoter of miR-488* in ASTN 1 gene. The 
mini gene construct (Exon 4, intron 4, exon 5 and a segment of 
intron 5 preceding precursor sequence of miR-488*) is to be 
cloned into pGL4.20 promoterless luciferase plasmid. 
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validation. Thus these transcription factors and promoter sequence could be 
used in future experiments for better understanding of the processing of miR-
488* in different cell lines as well as  aiming in future for drug therapy in prostate 
cancer by controlling the expression of miR-488*.  
4.3 Library of miR-488* Target site: 
 
The role of hsa-miR-488* in biological processes is not fully understood. 
TARGETSCAN bioinformatic program has predicted many target sites for miR-
488* in the human genome. Some of these targets are encoded in genes 
involved in Alternative splicing (LILRA2 gene). Some are involved in mRNA 
splicing regulation spliceosome-associated protein (KIAA 1429 gene). Other play 
a role in tumor suppression (ARMCX2 gene), and other may play a regulatory 
role in RNA editing (ADARB2 gene) (Figure 26). These results implicate further 
Figure 26: Examples of miR-488* targets sites in 3’UTR of their perspective genes:
Base pair interaction between miR-488* and target sites were predicted by TARGETSCAN
microRNA target prediction program and validated through RNAhybrid Algorithm. 
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importance of miR-488* in regulating biological processes. One of the future aims 
is to build a genome wide library of miR-488* target sites in 3’UTR that allows us 
to further study the implication of miR-488*. 
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4.4 Conclusion: 
 
A number of studies have provided insight into molecular mechanisms that 
contribute to the onset and progression of prostate cancer. Androgens play an 
important role in the development, regulation, and maintenance of the male 
phenotype as well as the reproductive physiology and have been implicated in 
the development and progression of prostate cancer. Androgens are required 
mitogens for the survival and proliferation of prostate cells and most prostate 
cancers are treated by complete blockade of androgen. AR is heterogeneously 
expressed in primary tumors, and throughout the progression of hormone-
sensitive and hormone-refractory prostate cancers. AR is a prominent target for 
the treatment of non-organ confined prostate cancer by hormonal blockade 
therapy that uses anti-androgens to competitively inhibit the binding of androgen 
to the ligand binding domain of the receptor. In prostate carcinogenesis, changes 
in AR signaling pathways activate the growth of malignant cells. The hormone-
refractory stage of the disease is commonly associated with the constitutive 
activation of AR expression by unknown mechanisms.  
Noncoding RNAs play diverse functions including structural, enzymatic 
and regulatory in metazoan gene expression. Genes that are potentially targeted 
by these miRNAs include cell growth and maintenance, signal transduction, cell 
proliferation, phosphorylation, cell cycle, transcription factors, cell organization 
and biogenesis etc. MiRNA mediates gene expression through translational 
repression of its target by binding at the 3’ untranslated region. In this work, our 
computational analysis has identified a target site of Hsa-miR-488* in the 
 61 
 
androgen receptor 3’ untranslated region.  The chimeric AR3’UTR luciferase 
plasmid sensor experiment suggested that the predicted target site is an 
authentic target site. Seed region within target is essential for the binding with 
miR-488*. Four base pairs mutations to the seed region is enough to disrupt the 
base paring interaction between that target site and the miR-488*. Furthermore, 
western blot data shows repression in the expression of endogenous Human 
androgen receptor in LNCaP cells by miR-488* mimic. Ectopically expressed 
mature miR-488* has a dose dependent repression of Firefly luciferase reporter 
plasmid. Stably expressed miR-488* in androgen dependent prostate cancer cell 
line (LNCaP) showed slower growth comparing to the miR-488* stably 
transfected androgen independent cell line (C4-2B). 
In conclusion, miR-488* is down regulated in numerous prostate cancer 
cell lines, suggesting a tumor-inhibitory function of Hsa-miR-488*. That being 
said, further investigations are required to fully understand the molecular 
mechanisms underlying the regulation of AR expression by miR-488*. Thus 
further knowledge of the functions and the mechanisms of miR-488* expression 
could significantly improve our understanding regarding the use of microRNAs as 
a therapeutic interventions of prostate cancer. 
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Appendices 
 
Table 1: Host genes, chromosomes and miRNA distribution: The table illustrates 
examples of conserved miRNAs with their host genes and gene IDs.  
 
 
Figure 1:  Alignments of the  stem loop of miRNAs 483 of human, mouse and rat : 
The figure illustrates a representative dataset showing conserved sequence elements 
found  in stem loop sequences of the miRNA of human, mouse and rat. An 81.5% of 
total conservation is observed. 
 
 
 
 
1 7610 20 30 40 50 60(1)
GAGGGGGAAGACGGGAGGAAAGAAGGGAGUGGUUCCAUCACGCCUCCUCACUCCUCUCCUCCCGUCUUCUCCUCUCHsa-mir-483 (1)
GAGGGGGAAGACGGGAGAAGAGAAGGGAGUGGUU---UUUGGGUGCCUCACUCCUCCCCUCCCGUCUUGUUCUCUCMmu-mir-483 (1)
GAGGGGGAAGACGGGAGAAGAGAAGGGAGUGGUU---UUUGGGUGCCUCACUCCUCCCCUCCCGUCUUGUUCUCUCRno-mir-483 (1)
GAGGGGGAAGACGGGAGAAGAGAAGGGAGUGGUU  UUUGGGUGCCUCACUCCUCCCCUCCCGUCUUGUUCUCUCConsensus (1)
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1 CCTCCTTGTC AACCCTGTTT TTCTCCCTCT TATTGTTCCC TACAGATTGC GAGAGAGCTG 
61 CATCAGTTCA CTTTTGACCT GCTAATCAAG TCACACATGG TGAGCGTGGA CTTTCCGGAA 
121 ATGATGGCAG AGATCATCTC TGTGCAAGTG CCCAAGATCC TTTCTGGGAA AGTCAAGCCC 
181 ATCTATTTCC ACACCCAGTG AAGCATTGGA AACCCTATTT CCCCACCCCA GCTCATGCCC 
241 CCTTTCAGAT GTCTTCTGCC TGTTATAACT CTGCACTACT CCTCTGCAGT GCCTTGGGGA 
301 ATTTCCTCTA TTGATGTACA GTCTGTCATG AACATGTTCC TGAATTCTAT TTGCTGGGCT 
361 TTTTTTTTCT CTTTCTCTCC TTTCTTTTTC TTCTTCCCTC CCTATCTAAC CCTCCCATGG 
421 CACCTTCAGA CTTTGCTTCC CATTGTGGCT CCTATCTGTG TTTTGAATGG TGTTGTATGC  
481 CTTTAAATCT GTGATGATCC TCATATGGCC CAGTGTCAAG TTGTGCTTGT TTACAGCACT 
541 ACTCTGTGCC AGCCACACAA ACGTTTACTT ATCTTATGCC ACGGGAAGTT TAGAGAGCTA 
601 AGTAATAGAC CCGAAATCAA AACAAAAACA AGCAAAC  
 
Figure2: Androgen Receptor 3’ untranslated region. The figure illustrates the AR 
3’UTR sequence (637 bases) with the predicted target site of miR-488* underlined and 
highlighted in red color. Target site consists of 24 nucleotides between base 589 and 
base 612. 
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Figure 3: pMIR-Report and an assay for mRNA specific miR function. The figure 
represents pMIR-Report Luciferase vector with the tow restriction sites (SpeI and HindII) 
at the far ends of the MCS. Figure 3A and 3B are an illustration of the assay for AR 
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3’UTR specific microRNA function. Figure 3A is a representation of luciferase gene 
cloned downstream of CMV promoter. Figure 3B is the chimeric luciferase sensor 
plasmid with AR3’UTR downstream of the luciferase gene. 
 
 
A 
 
Figure 4A: AR 3’ UTR with three substitution binding sites for miR-488*. miR-488* 
substitution sites are indicated as site 1, site 2 and site 3. Bases are highlighted in red. 
These three sites might serve as substitution targets for miR-488*. 
 
B 
 
Figure 4B: Schematic representation of segments of AR3’UTR cloned in pMIR 
report vector. Full length AR3’UTR (637 bases) with the miR-488* predicted site is 
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shown in green box. Site 1 (nucleotides 158-168 from 5’ end of AR 3’UTR) consists of 
10 nucleotides with 7 perfect matches to the seed region. Site 2 (nucleotides 293-299 
from 5’ end of AR 3’UTR) has 6 nucleotides with 4 perfect matches to the seed region 
and Site 3 (nucleotides 348-358 from 5’ end of AR 3’UTR) is composed of 10 
nucleotides with 8 perfect matches to the seed region. Short AR 3’UTR (77 bases) 
spanning between nucleotide 561 and nucleotide 637. 
 
 
 
 
 
Figure 5: Quantitative analysis of the repression of Luciferase sensor harboring 
individual mutations to site 1 , site 2 and site 3 by miR-488* mimic. Repression 
levels of firefly luciferase ( 54%, 53% and 52% ) for mutated site 1, mutated site 2 and 
mutated site 3 respectively as compared to seed MUT AR 3’UTR with 51% firefly 
luciferase repression. 
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Figure 6: Pre-miR-488* expression vector. The 383bp segment of intron five of 
ASTN1 containing precursor sequence for miR 488* and flanking region was PCR 
amplified and cloned downstream of CMV promoter into the MCS of pcDNA 3.1 (-) 
vector. 
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Figure 7: TaqMan MicroRNA Assay. The step one shows the extraction of total RNA. 
Step 2 illustrates the Reverse Transcription of RNA. The step 3 demonstrates the set up 
of Singleplex taqMan microRNA Assay reaction. Finally, the step 4 shows the Real-time 
PCR amplification followed by analysis of the data in step 5. 
 
 
 
 
 
